Lisaftoclax is a dual Bcl-2 and Bcl-xl inhibitor (IC50: 2 nM and 5.9 nM) with antitumor activity.

 

Brand: BCM

 

Solubility: Soluble in MSO.

 

Signaling Pathways: Apoptosis

 

Isomeric SMILES: C1CC2(C1)CCC(=C(C2)C3=CC=C(C=C3)Cl)CN4CCN(CC4)C5=CC(=C(C=C5)C(=O)NS(=O)(=O)C6=CC(=C(C=C6)NC[C@H]7COCCO7)[N+](=O)[O-])OC8=CN=C9C(=C8)C=CN9  

 

InChIKey: FNBXDBIYRAPDPI-BHVANESWSA-N  

 

InChI: InChI=1S/C45H48ClN7O8S/c46-33-4-2-30(3-5-33)39-25-45(12-1-13-45)14-10-32(39)28-51-16-18-52(19-17-51)34-6-8-38(42(23-34)61-35-22-31-11-15-47-43(31)49-26-35)44(54)50-62(57,58)37-7-9-40(41(24-37)53(55)56)48-27-36-29-59-20-21-60-36/h2-9,11,15,22-24,26,36,48H,1,10,12-14,16-21,25,27-29H2,(H,47,49)(H,50,54)/t36-/m0/s1

 

Attribute
[Chem Name]	4-[4-[[8-(4-chlorophenyl)spiro[3.5]non-7-en-7-yl]methyl]piperazin-1-yl]-N-[4-[[(2S)-1,4-dioxan-2-yl]methylamino]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
[Synonym]	Lisaftoclax; Lisaftoclaxum; APG-2575; Bcl-2/Bcl-xl inhibitor 1
[CAS No.]	2180923-05-9
[MDL No.]	MFCD34469554
[Formula]	C45H48ClN7O8S
[Molecular]	882.42
[Form]	Light yellow to yellow solid powder
[Storage]	Store at -20°C

Goods Tag